Breast Cancer

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

Richa Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

During a recent OncLive Peer Exchange®, the expert panel focused on the development of immunotherapy and other notable successes based on recent presentations at the 2019 San Antonio Breast Cancer Symposium.

Hernan Vargas, MD, FACS, a breast surgeon at Virginia Cancer Specialists, discusses the utility of sentinel lymph node biopsy in breast cancer.

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

Sara A. Hurvitz, MD, discusses available treatment options in early-stage HER2-positive breast cancer.

Oludamilola (Lola) A. Olajide, MD, discusses managing the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in breast cancer.

Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.

Several faculty who were on site at the 2020 Miami Breast Cancer Conference touch upon COVID-19.

Elisa Krill-Jackson, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in the treatment of patients with metastatic breast cancer.

What may have worked before to mitigate burnout may no longer work now because we change, and so do our work environments.

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

Special attention to reducing the risk of cardiovascular disease should be a priority for long-term care of patients with breast cancer.

Patrick I. Borgen, MD, discusses the trend toward surgical de-escalation in patients with breast cancer.

Enrique Soto Pérez de Celis, MD, MSc, discusses nuances of treating older patients with breast cancer.

Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.

Hope S. Rugo, MD, discusses the pending approval of tucatinib in metastatic HER2-positive breast cancer and other potentially practice-changing agents in the pipeline.

Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.

Breast cancer has historically been an immunologically cold disease, but recent and emerging data are carving out a space for several immunotherapies in the treatment paradigm.

Kevin Hughes, MD, discusses the role of genetic testing in breast cancer.